You are here: Industry Insights > Ascletis

News List

Shanghai Public Health Clinical Center Initiated Functional Cure Study of Anti-PD-L1 Antibody ASC22 (Envafolimab) in Combination With Chidamide in HIV-Infected Patients prnasia
February 15, 2022
Ascletis Pharma Inc. (HKEX: 1672) today announces that Shanghai Public Health Clinical Center initiated functional cure study of anti-PD-L1 antibody ASC22 (Envafolimab) in combination with Chidamide...
Ascletis announces signing of Ritonavir tablet purchase agreement with Phokam Pharmaceutical ExpressPharma
January 20, 2022
Ascletis Pharma Inc recently announced the signing of the Ritonavir tablet purchase agreement between Phokam Pharmaceutical Import-Export (as buyer) of Laos and Ascletis Pharmaceuticals (as seller), a wholly-owned subsidiary of Ascletis Pharma Inc.
Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab), a Subcutaneously Administered PD-L1 Antibody for Functional Cure of Chronic Hepatitis B prnasia
January 18, 2022
Ascletis Pharma Inc. (HKEX: 1672) announces today the Investigational New Drug (IND) application approval by U.S. Food and Drug Administration (FDA) and initiation of global development of ASC22 (Envafolimab)...
Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of FASN Inhibitor ASC40 for Treatment of Moderate to Severe Acne prnasia
January 14, 2022
Ascletis Pharma Inc. (HKEX: 1672) today announces the dosing of the first patient in the Phase II clinical trial of ASC40 for moderate to severe acne. ASC40 is an oral, selective inhibitor of fatty acid synthase (FASN)...
Ascletis Announces First Patient Dosed in the Phase II Clinical Trial of ASC42, An In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication prnasia
January 11, 2022
Ascletis Pharma Inc. (HKEX: 1672) today announces the dosing of the first patient in the Phase II clinical trial of ASC42 for chronic hepatitis B (CHB) indication.
Ascletis Announces U.S. IND Filing for In-House Developed Oral PD-L1 Small Molecule Inhibitor ASC61 for Treatment of Advanced Solid Tumors prnasia
January 10, 2022
Ascletis Pharma Inc. (HKEX: 1672) announces today the filing of the U.S. Investigational New Drug (IND) application for in-house developed oral PD-L1 small molecule inhibitor, ASC61, for the treatment of advanced solid tumors.
Ascletis Expands Ritonavir Oral Tablet Production and Announces Oral Direct-Acting Antiviral Pipeline Against SARS-CoV-2 Virus prnasia
January 04, 2022
Ascletis Pharma Inc. (HKEX: 1672) today announces the expansion of the production of ritonavir oral tablets and oral direct-acting antiviral R&D pipeline for the treatment of SARS-CoV-2 infection.
Ascletis expands ritonavir oral tablets production amid Covid-19 surge pharmaceutical-business-review
January 03, 2022
ascletis Pharma is expanding the production of ritonavir oral tablets as well as the oral direct-acting antiviral R&D pipeline to treat SARS-CoV-2 virus amid the recent surge in Covid-19 cases.
Ascletis Expands Ritonavir Oral Tablet Production contractpharma
January 03, 2022
Also announces oral direct-acting antiviral pipeline against SARS-CoV-2 virus.
Clinical Studies of PD-L1 Antibody ASC22 for HBV Functional Cure Selected for Inclusion in the "Best of The Liver Meeting's Summary" by AASLD Review Committee prnasia
November 16, 2021
Ascletis Pharma Inc. (HKEX: 1672) announces today that Phase IIa and IIb clinical studies of PD-L1 antibody ASC22 (Envafolimab) for Hepatitis B Virus (HBV) functional cure have been selected for inclusion...

Previous page 1 2 3 4 5 Next page